Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 7

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 7
---
 Moore Financial Consulting, or Moore, as more fully described in the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.” As a condition to Closing, on the Effective Time, SKNY must hold at least $5 million in either cash, marketable securities or a combination of cash and marketable securities. At the Effective Time, MIRA’s stockholders will continue to own and hold their existing shares of MIRA Common Stock. Following the Merger, MIRA’s shares will continue to be listed on the Nasdaq under the symbol “MIRA”.

Q: What will happen to MIRA if, for any reason, the Merger does not close?

A:If, for any reason, the Merger does not close, the board of directors of MIRA (the “MIRA Board”) may elect to, among other things, attempt to complete another strategic transaction similar to the Merger.

Q: Why are the two companies proposing to merge?

A:The Merger will result in a biopharmaceutical company focused on the development and potential commercialization of several novel, potentially first-in-class product candidates targeting multiple therapeutic areas, including smoking cessation, obesity, pain management, depression, post-traumatic stress disorder (PTSD), and cognitive impairment. For a discussion of MIRA’s reasons for the Merger, please see the section titled “ The Merger— Background of the Merger.”

Q: Why am I receiving this proxy statement?

A:You are receiving this proxy statement because you have been identified as a holder of MIRA Common Stock as of the record date, and you are entitled to vote at the MIRA virtual special meeting to approve the matters described in this proxy statement. This proxy statement contains important information about the MIRA virtual special meeting, the Merger, the Merger Agreement and the other business to be considered by MIRA stockholders at the MIRA virtual special meeting and you should read it carefully and in its entirety. The enclosed voting materials allow you to authorize a proxy to vote your shares of MIRA Common Stock without attending the MIRA virtual special meeting. As promptly as practicable, please complete, sign, date and mail your proxy card in the pre-addressed postage-paid envelope provided or call the toll-free telephone number listed on your proxy card or access the internet website described in the instructions on the enclosed proxy card.

Q: What am I voting on?

A:Holders of MIRA Common Stock as of the record date are entitled to vote at the MIRA virtual special meeting on